This connection further underscores the potential for targeting KCa3.1 as a therapeutic strategy for atherosclerosis, as improving mitochondrial function and activating PPAR pathways could collectively reduce vascular inflammation, improve plaque stability, and limit disease progression. This evidence concerns the gene PPARA and atherosclerosis.